Literature DB >> 15004761

Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.

Valeria Ghisetti1, Alfredo Marzano, Fausto Zamboni, Anna Barbui, Alessandro Franchello, Silvia Gaia, Giovanna Marchiaro, Mauro Salizzoni, Mario Rizzetto.   

Abstract

Occult Hepatitis B virus (o-HBV) infection has been reported in HB surface antigen (HBsAg)-negative liver donors whose risk of transmitting HBV justifies a specific prophylaxis in liver recipients. The clinical significance of o-HBV infection in HBsAg-negative recipients and their need for prophylaxis is unknown. Liver samples collected during surgery from 23 HBsAg-negative patients (9 liver donors and 14 recipients) and 20 HBsAg-positive recipients (controls) were studied by polymerase chain reaction with an independent set of primers mapping the core and surface HBV genes. Intrahepatic HBV DNA was detected as core and surface genes in all the HBsAg-positive recipients, in none of the HBsAg-negative donors and in 9/14 (64%) of the HBsAg-negative recipients (2 HCV negative, 7 HCV positive). The intrahepatic amount of HBV was significantly lower in HBsAg-negative than in HBsAg-positive livers (median values 1.36 Log(10)/microg DNA vs. 3.66 Logs, p<0.0001, core gene, and 1.13 vs. 6.21 Logs p<0.0001, surface gene). No HBV DNA was detected in plasma from o-HBV recipients; one of them tested positive in lymphocytes. No correlation was found between o-HBV and serologic markers of previous HBV exposure, response to vaccination, acute rejection, hepatitis D and G virus-infections. None of o-HBV carriers experienced a de novo hepatitis B after transplantation (median follow-up: 477 days). Occult HBV is frequent in HBsAg-negative liver recipients. It is not associated with increased episodes of acute rejection, coinfection with hepatotropic viruses, different responses to HBV vaccination, or the development of de-novo hepatitis B. In o-HBV infection a particular virus-host interaction can explain the low intrahepatic HBV content and the lack of extrahepatic HBV replication, thus justifying the low risk of hepatitis B reactivation, in absence of specific prophylaxis, once the recipient liver is removed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004761     DOI: 10.1002/lt.20093

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  18 in total

Review 1.  Occult hepatitis B: clinical implications and treatment decisions.

Authors:  Paul Schmeltzer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

2.  Significance of a single-nucleotide primer mismatch in hepatitis B virus real-time PCR diagnostic assays.

Authors:  Chun-Kin Chow; Kun Qin; Lok-Ting Lau; Albert Cheung-Hoi Yu
Journal:  J Clin Microbiol       Date:  2011-12       Impact factor: 5.948

3.  COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.

Authors:  Tiziano Allice; Francesco Cerutti; Fabrizia Pittaluga; Silvia Varetto; Silvia Gabella; Alfredo Marzano; Alessandro Franchello; Giuseppe Colucci; Valeria Ghisetti
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

Review 4.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

5.  Risk of hepatitis B infections in Olympic wrestling.

Authors:  S Bereket-Yücel
Journal:  Br J Sports Med       Date:  2007-03-01       Impact factor: 13.800

6.  Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination.

Authors:  Qing-Qing Yao; Xiao-Lian Dong; Xue-Cai Wang; Sheng-Xiang Ge; An-Qun Hu; Hai-Yan Liu; Yueping Alex Wang; Quan Yuan; Ying-Jie Zheng
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

7.  Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples.

Authors:  Perumal Vivekanandan; Rajesh Kannangai; Stuart C Ray; David L Thomas; Michael Torbenson
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

8.  Prophylaxis of hepatitis B infection in solid organ transplant recipients.

Authors:  Savio John; Karin L Andersson; Camille N Kotton; Martin Hertl; James F Markmann; A Benedict Cosimi; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

Review 9.  Molecular testing in the diagnosis and management of chronic hepatitis B.

Authors:  Alexandra Valsamakis
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

10.  High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.

Authors:  Eung Chang Lee; Seong Hoon Kim; Seung Duk Lee; Hyeongmin Park; Soon-Ae Lee; Sang-Jae Park
Journal:  World J Gastroenterol       Date:  2016-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.